Trials / Unknown
UnknownNCT04846842
A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
A Phase II Study of Gimatecan in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Lee's Pharmaceutical Limited · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II clinical trial studies the safety and effect of Gimatecan in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or peritoneal cancer. The chemotherapy will be given every four weeks.This study is a single-arm, multi-center research design.
Detailed description
The study had 3 phases: screening phase, treatment phase and follow-up phase. During the treatment phase, the drug will continue to be administered until the progression of disease, complete remission , unacceptable toxicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gimatecan | Patients will receive gimatecan orally at the fixed dose level on day 1-5 every 4 weeks. |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2022-07-01
- Completion
- 2023-07-01
- First posted
- 2021-04-15
- Last updated
- 2021-04-19
Source: ClinicalTrials.gov record NCT04846842. Inclusion in this directory is not an endorsement.